China National Accord Medicines Corporation Ltd. (SHE:000028)
China · Delayed Price · Currency is CNY 25.45
+0.01 (0.04%)
Mar 26, 2026, 2:15 PM CST
SHE:000028 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 73,416 | 73,675 | 74,844 | 72,701 | 67,648 |
Other Revenue | - | 703 | 633.35 | 742.57 | 710.01 |
| 73,416 | 74,378 | 75,477 | 73,443 | 68,358 | |
Revenue Growth (YoY) | -1.29% | -1.46% | 2.77% | 7.44% | 14.60% |
Cost of Revenue | 71,903 | 66,180 | 66,471 | 64,561 | 60,372 |
Gross Profit | 1,513 | 8,198 | 9,006 | 8,883 | 7,986 |
Selling, General & Admin | - | 6,407 | 6,404 | 6,374 | 5,772 |
Research & Development | - | 24.55 | 26.82 | 9.07 | - |
Other Operating Expenses | - | 158.44 | 93.73 | 180.1 | 139.09 |
Operating Expenses | - | 6,684 | 6,596 | 6,585 | 5,955 |
Operating Income | 1,513 | 1,514 | 2,411 | 2,298 | 2,031 |
Interest Expense | - | -258.3 | -248.38 | -261.91 | -288.04 |
Interest & Investment Income | - | 300.32 | 314.58 | 212.07 | 366.68 |
Currency Exchange Gain (Loss) | - | -1.85 | 2.95 | -0.44 | 0.41 |
Other Non Operating Income (Expenses) | -3.81 | -15.44 | -27.9 | -1.89 | -4.87 |
EBT Excluding Unusual Items | 1,509 | 1,539 | 2,452 | 2,245 | 2,105 |
Impairment of Goodwill | - | -887.85 | - | -38.98 | -162.69 |
Gain (Loss) on Sale of Investments | - | -22.81 | -15.16 | 28.87 | - |
Gain (Loss) on Sale of Assets | - | 11.87 | 45.31 | 8.31 | 4.25 |
Asset Writedown | - | -84 | -0.64 | -18.87 | -75.55 |
Legal Settlements | - | -0.51 | -3.25 | -0.05 | -0.55 |
Other Unusual Items | - | 19.81 | -5.12 | 86.36 | 104.09 |
Pretax Income | 1,509 | 575.47 | 2,473 | 2,311 | 1,975 |
Income Tax Expense | 373.09 | 338.47 | 514.74 | 539.33 | 447.21 |
Earnings From Continuing Operations | 1,136 | 237 | 1,958 | 1,772 | 1,528 |
Minority Interest in Earnings | - | 405.49 | -359.23 | -285.03 | -191.21 |
Net Income | 1,136 | 642.49 | 1,599 | 1,487 | 1,336 |
Net Income to Common | 1,136 | 642.49 | 1,599 | 1,487 | 1,336 |
Net Income Growth | 76.80% | -59.82% | 7.57% | 11.24% | -4.67% |
Shares Outstanding (Basic) | 557 | 557 | 557 | 557 | 557 |
Shares Outstanding (Diluted) | 557 | 557 | 557 | 557 | 557 |
Shares Change (YoY) | 0.05% | -0.12% | 0.12% | - | - |
EPS (Basic) | 2.04 | 1.15 | 2.87 | 2.67 | 2.40 |
EPS (Diluted) | 2.04 | 1.15 | 2.87 | 2.67 | 2.40 |
EPS Growth | 77.39% | -59.93% | 7.49% | 11.25% | -4.59% |
Free Cash Flow | - | 2,989 | 2,615 | 2,238 | 1,285 |
Free Cash Flow Per Share | - | 5.37 | 4.69 | 4.02 | 2.31 |
Dividend Per Share | - | 0.366 | 0.680 | 0.615 | 0.462 |
Dividend Growth | - | -46.18% | 10.50% | 33.35% | -25.01% |
Gross Margin | 2.06% | 11.02% | 11.93% | 12.09% | 11.68% |
Operating Margin | 2.06% | 2.04% | 3.19% | 3.13% | 2.97% |
Profit Margin | 1.55% | 0.86% | 2.12% | 2.02% | 1.96% |
Free Cash Flow Margin | - | 4.02% | 3.46% | 3.05% | 1.88% |
EBITDA | 1,736 | 1,737 | 3,836 | 2,542 | 2,239 |
EBITDA Margin | 2.36% | 2.34% | 5.08% | 3.46% | 3.28% |
D&A For EBITDA | 222.98 | 222.98 | 1,426 | 244.32 | 207.45 |
EBIT | 1,513 | 1,514 | 2,411 | 2,298 | 2,031 |
EBIT Margin | 2.06% | 2.04% | 3.19% | 3.13% | 2.97% |
Effective Tax Rate | 24.72% | 58.82% | 20.81% | 23.34% | 22.64% |
Revenue as Reported | - | 74,378 | 75,477 | - | - |
Advertising Expenses | - | - | - | 46.67 | 44.12 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.